Evaluation of 311 contemporary cases of stereotactic biopsies in patients with neoplastic and non-neoplastic lesions—diagnostic yield and management of non-diagnostic cases

Krystyna Agnieszka Pasternak 1 · Michael Schwake 1 · Nils Warneke 1 · Max Masthoff 2 · Samer Zawy Alsofy 3,4 · Eric Suero Molina 1 · Walter Stummer 1 · Stephanie Schipmann 1

Received: 29 June 2020 / Revised: 26 August 2020 / Accepted: 15 September 2020 / Published online: 20 September 2020
© The Author(s) 2020, corrected publication 2021

Abstract
Stereotactic biopsies are an established tool for obtaining diagnosis of unclear brain lesions. However, non-diagnostic biopsies still occur. We aimed to analyze the contemporary diagnostic yield of stereotactic biopsies, predictors for non-diagnostic biopsies, outcome, and follow-up strategy after non-diagnostic biopsy. We conducted a single-center retrospective study of 311 adult patients undergoing stereotactic biopsies due to a newly diagnosed lesion at our department between 2012 and 2018. Patient data regarding comorbidities, presenting symptoms, imaging features, and non-invasive diagnostic procedures were obtained. The overall diagnostic yield was 86.2% and differed significantly between the various suspected diagnosis groups and was the highest when suspecting primary brain tumor compared with non-neoplastic lesions (91.2% vs. 73.3%, \( p > 0.001 \)). Predictors for non-diagnostic biopsies were small lesion size, lack of contrast-enhancement, presence of sepsis, or underlying hemato-oncological disease. In case of non-diagnostic biopsy, a re-biopsy was performed in 12 cases, revealing a final diagnosis in 75%. In 16 cases, empiric therapy was started based on the suspected underlying disease. Close follow-up was performed in the remaining 15 cases. We showed that stereotactic biopsy is a safe procedure with reasonable diagnostic yield even for non-neoplastic lesions, when non-invasive diagnostic was inconclusive. In addition, we developed treatment recommendations for cases of non-diagnostic biopsies.

Keywords
Stereotactic biopsy · Brain lesion · Diagnostic yield · Non-diagnostic biopsy · Glioma · Vasculitis

Introduction
Stereotactic biopsy techniques have been widely used since the 1940s and have become an important neurosurgical tool in the diagnosis of intracranial lesions [11]. Apart from primary and secondary brain tumors, lesions can be of inflammatory, infectious, of autoimmune or vascular etiology. Regardless of the etiology, each case demands an accurate and precise histological diagnosis. Many studies demonstrate that stereotactic biopsy techniques enable retrieving tissue even from deep-seated small lesions with comparable low mortality and morbidity [6, 7, 13, 17, 29]. However, with up to 19%, a significant number of non-diagnostic biopsies are reported, especially in patients with non-tumorous lesions [5, 14, 24]. Without obtaining a diagnosis, treatment of the underlying diagnosis is challenging and might be delayed leading to a worse outcome.

We aimed to analyze all cases requiring a stereotactic biopsy at our department regarding diagnostic yield and the underlying etiology of the lesion, paying special attention to factors associated with non-diagnostic biopsies and discuss the outcome and clinical management of those patients.

Material and methods
We performed a retrospective analysis of all adult patients presenting with newly diagnosed cerebral lesions of unknown
etiology that was not amenable to primary surgical resection between January 2012 and December 2018 to our tertiary care neurosurgical department. We enrolled only patients that consecutively were managed by stereotactic needle biopsy.

**Routine management of patients with unclear cerebral lesions**

Prior to surgery, all patients presenting with an indeterminate cerebral lesion underwent magnetic resonance (MR) imaging and in selected cases, e.g., when suspecting an underlying low-grade glioma additional 18-F-fluoroethyl-tyrosine (FET)-positron emission tomography (PET) to define hypermetabolic areas.

Each case was discussed by a team of consultant neurosurgeons, neuroradiologists and neurologists, and the attending physician within an interdisciplinary board. In cases of suspected inflammatory disorder or vasculitis, non-surgical tests such as CSF analysis, including microbiologic and virologic analysis, were performed in advance. Only unclear cases or cases where tissue diagnosis was mandatory were scheduled for needle biopsy. A needle biopsy was also performed in patients with tumors that were ineligible for resection due to poor general condition or eloquence of tumor location.

After induction of general anesthesia, a stereotactic head frame was mounted to the head. The stereotactic system was chosen by the attending neurosurgeon according to their preference. The stereotactic system by KD Lerch (CL Instruments GmbH, Attendorn, Germany) was used between 2012 and 2014 and replaced by Leksell (Elekta, Stockholm, Sweden) and ZD (Zamorano-Duchovny) stereotactic system (Inomed GmbH, Emmendingen, Germany) after 2014.

A 1-mm slice contrast-enhanced CT scan was subsequently acquired. Needle trajectory, entry point, and biopsy targets were determined using iPlan Stereotactic planning software Version 3.0 (BrainLab AG, Munich, Germany). Preoperative MRI (0.6 mm MPR T1Gd or FLAIR) and PET images, as available, were fused with the acquired CT scan for precise target and safe entry point selection. A contrast-enhanced region of the lesion—if applicable—was targeted. The stereotactic system was mounted and a 3-cm scalp incision followed by a single burr hole was placed at the planned entry site. Depending on the size of the lesion, approximately 10-mm-long and 1.5-mm-thick serial tissue biopsies with 2.1-mm needles (Neuromedex, Hamburg, Germany) were collected throughout the lesion. In case of suspected vasculitis, additional biopsies were taken from dura, arachnoid, and cortex. We aimed to use a trajectory that is as vertical as possible to cortex and lesion and hereby sparing sulci, blood vessels, and ventricles.

For frameless stereotactic biopsy, a 3-point Mayfield clamp was fastened to the head and the BrainLab VarioGuide System and software (iPlan 3.0 and Elements, BrainLab AG, Munich, Germany) were used as previously described [10]. For deep-seated lesions, frames were used, whereas for more superficial lesions, the attending surgeon could choose between a frame-based or frameless procedure.

After the procedure, patients were observed for neurological deterioration in the intensive care unit. A postoperative cranial CT scan was performed the following day to confirm location of the biopsy and to rule out hemorrhage.

**Patient data**

The electronic medical records of each patient were reviewed and baseline demographic data as well as patients’ comorbidities, presenting symptoms, surgical characteristics, and laboratory features were obtained. In addition, lesion features such as depth, size, and location, e.g., multifocality and radiological features such as contrast enhancement and presence of edema were assessed during reviews of imaging by two independent authors.

Cerebrospinal fluid (CSF) was obtained in cases with suspected inflammatory disorder or in case of lymphoma prior to biopsy. Abnormal results were defined as elevated cell count, protein elevation, presence of pathogens, or pathological cells. Neuropathological and, if appropriate, microbiological diagnoses were obtained from biopsies. Neuropathological diagnosis was reported according to the criteria of the 2016 World Health Organization (WHO) classification of Central Nerve System (CNS) tumors [20].

The primary outcomes were diagnostic yield, representing the percentage of cases with a definitive neuropathological diagnosis after biopsy, and procedure-related morbidity and mortality. In addition, in case of non-diagnostic biopsies, the subsequent clinical course and treatment strategies were evaluated.

Informed consent was obtained from each patient. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Ref 2019-379-f-S) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Statistical analysis**

For statistical analysis, IBM SPSS Statistics 25.0 software (IBM, Armonk, NY, USA) was used. Data was described by standard statistics, using absolute and relative frequencies for categorical variables and median with interquartile range for continuous variables.

Chi-square test and t test or Mann-Whitney U test were used for categorical and continuous variables, respectively. All factors that showed statistical significance in univariate analysis were combined in a multivariate logistic regression model. Odds ratios (OR) were obtained with corresponding 95% confidence intervals (CI). Patients with missing information about one variable were only excluded from the corresponding...
statistical analyses but not from the entire study. Statistical significance was defined as the probability of a type one error below 5% (p < 0.05).

Results

Patient data

A total of 311 patients diagnosed with an unclear cerebral lesion underwent stereotactic surgery and were included into analysis. Mean patient age was 61 years (IQR 24), 55.6% (173/311) were male, and 44.4% (138/311) were female. Most patients presented with motor deficits (35.4%, 110/311) or cognitive deficits (27.3%, 85/311); in the majority of cases (43.5%, 131/301), symptom onset was more than 1 month prior to presenting to our department. Lesions were deep seated (thalamus, brain stem, midline structure, basal ganglia) in 17% (53/311).

In almost half of all cases, the suspected diagnosis was primary brain tumor (47.6%, 148/311). Prior to needle biopsy, one-quarter of all patients (76/311) received steroids. Further baseline characteristics regarding comorbidities and imaging features of the suspect cerebral lesions are listed in Table 1.

Pathological diagnoses and diagnostic yield

An overview of all neuropathological diagnoses of biopsies is given in Table 2. The main diagnosis was primary brain tumor in almost half of all cases (46.6%, 145/311). Grade IV, III, and II gliomas were reported in 69/145, 36/145, and 36/145 primary brain tumor cases, respectively. Considering the relevant molecular determinants for glioma from the new WHO brain tumor classification, IDH status was characterized in 83.4% (121/145) of all glioma cases and MGMT in 82.6% (90/109) of high-grade gliomas. When considering only biopsies performed after 2015, after introduction of the revised WHO classification [20], IDH was obtained in 96.9% (94/97) and MGMT in 92.8% (64/69) of high-grade glioma cases. The remaining cases did not allow MGMT and IDH analysis.

The samples were sufficient for diagnosis in 268 cases, giving an overall diagnostic yield of 86.2% (268/311). The diagnostic yield differed significantly between the various diagnosis subgroups and was highest in case of suspected primary and other brain tumors (91.2%, 135/148, and 91.7%, 11/12, respectively) and lowest in case of suspected underlying vascular disease, e.g., vasculitis (47.1%, 8/17) (p < 0.001, Fig. 1). The diagnostic yield was slightly higher with frame-based (87.2%, 205/235) than in the frameless (82.9%, 63/76) procedures, without reaching statistical significance (p = 0.341). When comparing all stereotactic systems used over time, biopsies obtained with the ZD or Leksell stereotactic systems were significantly more likely to be diagnostic (93.9%, 31/33 vs. 92.0%, 103/112, respectively) than using VarioGuide or KD Lerch system (82.9%, 63/76 vs. 78.9%, 71/90, respectively) (p = 0.023) (Table 1). The initially suspected diagnosis was confirmed in 203/311 cases (65.3%).

Factors associated with a non-diagnostic biopsy

In patients that suffered an underlying hemato-oncological disease and that were treated for sepsis, a non-diagnostic biopsy was more likely (Table 3). In contrast, larger lesions (>1cm³) were 7.5-fold and contrast-enhancing lesions almost 5-fold more likely to be diagnostic. The highest diagnostic yield could be achieved using the ZD stereotactic system (OR: 8.97 95% CI: 1.45–55.63, p = 0.018).

Complications and 30-day mortality

Postoperative complications occurred in 21 of 311 cases (6.8%); the main complication was the onset of a new neurological deficits (5.5%, 17/311), in some cases attributed to symptomatic intracranial hemorrhage (2.9%, 9/211), requiring re-operation. The 30-day mortality rate was 4.5% (14/311); however, only two of them (0.6%) were procedure-related (Table 4). The rate of a persisting neurologic deficit > 30 days was 3.9% (12/311). In a total of 248 cases, a routine postoperative CT was performed, showing, non-symptomatic hemorrhage in 26/248 (10.5%) of cases.

Non-diagnostic lesions

We identified 43/311 (13.8%) cases of non-diagnostic biopsies showing only reactive brain tissue in histopathological analysis despite immunohistochemical evaluations for IDH, MIB (Ki-67), or p53. Follow-up and outcome of these cases are presented in Fig. 2 and cases can be divided into three groups. Concordance between the definitive and intended biopsy localization was documented in 34/43 (79.1%) cases on postoperative CT scans. The remaining cases did not receive a postoperative scan.

Re-biopsy A re-biopsy was performed in 12/43 cases (27.9%), revealing a definitive diagnosis of primary brain tumor (7/12) and lymphoma (1/12) in 75%. These 8/12 cases with initial non-diagnostic biopsy and diagnostic result in repeat biopsy were subject to further analyses regarding reasons for non-diagnostic biopsy. In 5/7 cases (71.4%) that were diagnosed as glioma in repeat histology, the tumor infiltrating zone was presumably biopsied as initial histology revealed slightly higher proliferation rate and chronic inflammation without clear evidence for tumor cells. This could also be confirmed by postoperative MRI imaging, visualizing the biopsy localization. In two of these 7 cases (2/7, 28.6%), an open biopsy was performed, whereas in 5/7 cases (71.4%), the stereotactic
|                                | All cases n = 311 (%) | Diagnostic biopsy n (%) | Non-diagnostic biopsy n (%) | p value |
|--------------------------------|------------------------|-------------------------|-----------------------------|---------|
| **Age**                        |                        |                         |                             |         |
| Median, IQR                    | 61 (24)                | 118 (79.7)              | 30 (20.3)                   | 0.005   |
| 18–60 years                    | 148 (47.6)             | 150 (92.0)              | 13 (8.0)                    | 0.002   |
| > 60 years                     | 163 (52.4)             | 118 (85.5)              | 20 (14.5)                   | 0.761   |
| **Sex**                        |                        |                         |                             |         |
| Male                           | 173 (55.6)             | 150 (86.7)              | 23 (13.3)                   | < 0.001 |
| Female                         | 138 (44.4)             | 118 (85.5)              | 20 (14.5)                   |         |
| **Suspected diagnosis**        |                        |                         |                             |         |
| Primary brain tumor            | 148 (47.6)             | 135 (91.2)              | 13 (8.8)                    |         |
| Lymphoma                       | 73 (23.5)              | 63 (86.3)               | 10 (13.7)                   |         |
| Other tumor                    | 12 (3.9)               | 11 (91.7)               | 1 (8.3)                     |         |
| Inflammatory (autoimmune)     | 15 (4.8)               | 12 (80.0)               | 3 (20.0)                    |         |
| Inflammatory (infectious)      | 28 (9.0)               | 24 (85.7)               | 4 (14.3)                    |         |
| Vascular                       | 17 (5.5)               | 8 (47.1)                | 9 (52.9)                    |         |
| Unclear                        | 18 (5.8)               | 15 (83.3)               | 3 (16.7)                    |         |
| **Comorbidities**              |                        |                         |                             |         |
| Diabetes mellitus              | 43 (13.8)              | 38 (88.4)               | 5 (11.6)                    | 0.653   |
| Nicotine abuse                 | 31 (10.0)              | 24 (77.4)               | 7 (22.6)                    | 0.137   |
| Alcohol abuse                  | 7 (2.3)                | 7 (100)                 | 0 (0.0)                     | 0.284   |
| Drug abuse                     | 2 (0.6)                | 1 (50.0)                | 1 (50.0)                    | 0.137   |
| HIV                            | 2 (0.7)                | 0 (0.0)                 | 2 (100)                     | < 0.001 |
| Hepatitis B                    | 2 (0.7)                | 2 (100)                 | 0 (0.0)                     | 0.571   |
| Hepatitis C                    | 1 (0.4)                | 1 (100)                 | 0 (0.0)                     | 0.694   |
| Epilepsy                       | 25 (8.0)               | 20 (80.0)               | 5 (20.0)                    | 0.351   |
| Solid malignant tumor          | 34 (10.9)              | 30 (88.2)               | 4 (11.8)                    | 0.712   |
| Hemato-oncological disease     | 30 (9.6)               | 22 (73.3)               | 8 (26.7)                    | 0.032   |
| Chemotherapy (within last 3 months) | 8 (2.6) | 6 (75.0) | 2 (25.0) | 0.354 |
| Radiotherapy (within last 3 months) | 1 (0.3) | 0 (0.0) | 1 (100) | 0.012 |
| Autoimmune disease             | 17 (5.5)               | 13 (76.5)               | 4 (23.5)                    | 0.233   |
| Immunosuppression              | 11 (3.5)               | 6 (54.5)                | 5 (45.5)                    | 0.002   |
| Sepsis                         | 12 (3.9)               | 8 (66.7)                | 4 (33.3)                    | 0.046   |
| **Presenting symptoms**        |                        |                         |                             |         |
| Headache                       | 36 (11.6)              | 31 (86.1)               | 5 (13.9)                    | 0.991   |
| Dizziness                      | 33 (10.6)              | 26 (78.8)               | 7 (21.2)                    | 0.194   |
| Impaired vigilance             | 18 (5.8)               | 14 (77.8)               | 4 (22.2)                    | 0.288   |
| Seizure                        | 53 (17.0)              | 52 (98.1)               | 1 (1.9)                     | 0.006   |
| Cranial nerve dysfunction      | 35 (11.3)              | 31 (88.6)               | 4 (11.4)                    | 0.663   |
| Motor deficits                 | 110 (35.4)             | 93 (84.5)               | 17 (15.5)                   | 0.538   |
| Sensory deficits               | 27 (8.7)               | 21 (77.8)               | 6 (22.2)                    | 0.186   |
| Cognitive deficits             | 85 (27.3)              | 74 (87.1)               | 11 (12.9)                   | 0.782   |
| Aphasia                        | 54 (17.4)              | 44 (81.5)               | 10 (18.5)                   | 0.272   |
| Elevated intracranial pressure | 13 (4.2)               | 11 (84.6)               | 2 (15.4)                    | 0.868   |
| Incidental finding             | 6 (1.9)                | 6 (1000)                | 0 (0.0)                     | 0.322   |
| **Symptom onset**              |                        |                         |                             |         |
| Peracute (1–2 days)            | 27 (9.0)               | 24 (88.9)               | 3 (11.1)                    | 0.970   |
| Acute (3–10 days)              | 55 (18.3)              | 47 (85.5)               | 8 (14.5)                    |         |
| Subacute (11–30 days)          | 88 (29.2)              | 75 (85.2)               | 13 (14.8)                   |         |
| Chronic (> 1 month)            | 131 (43.5)             | 70 (85.5)               | 11 (14.5)                   |         |
| **Treatment before biopsy**    |                        |                         |                             |         |
| Steroids                       | 76 (24.4)              | 63 (82.9)               | 13 (17.1)                   | 0.194   |
| Immunosuppressants             | 6 (1.9)                | 1 (16.7)                | 5 (83.3)                    | < 0.001 |
| Anti-infective therapy         | 33 (10.6)              | 26 (78.8)               | 7 (21.2)                    | 0.301   |
| **Side of pathology**          |                        |                         |                             |         |
| Right                          | 95 (30.5)              | 83 (87.4)               | 12 (12.6)                   | 0.533   |
| Left                           | 95 (30.5)              | 84 (88.4)               | 11 (11.6)                   |         |
| Bilateral                      | 121 (38.9)             | 101 (83.5)              | 20 (16.5)                   |         |
biopsy was repeated. In the remaining glioma case (1/7), the target was initially missed with frameless technique and biopsy was repeated using a frame-based stereotactic procedure.

The first biopsy of the patients with later diagnosed lymphoma revealed reactive brain tissue while the postbiopsy CT indicated a correct localization of the biopsy. The second biopsy was taken from the other side where a clear tumor progress was seen after a few weeks, while the initial biopsy place remained without evidence for tumor progression. Diagnosis of lymphoma was delayed as the re-biopsy was performed 184 days after initial non-diagnostic biopsy, whereas the re-biopsy in case of primary brain tumor was performed within 4 weeks (median 16 days, range: 9–27).

Taken together, the reasons for these unclear biopsies can be classified as a target error.

In the remaining 4/12 cases (25%), a repeat biopsy could not confirm a diagnosis despite verification of correct biopsy localization on MRI in 2 cases and CT in 2 cases; both biopsies resulted in reactive brain tissue. No progression of the underlying lesion in these cases was observed during further follow-up.

There were no differences regarding application of steroids related to the validity of the biopsy in all mentioned cases.

**Empiric treatment** Based on the presumed underlying diagnosis (vascular, inflammatory, leukoencephalopathy), derived from clinical and additional laboratory and imaging findings, empiric treatment, using immunosuppressive agents and medication to control risk factors—as appropriate—and additional serial imaging were initiated in 16/43 cases (37.2%). None of these patients worsened clinically during a median follow-up of 37 months (range: 5–80) and symptoms improved in 11/16 cases (68.8%). One case was lost to follow-up.

**Follow-up (FU)** In the remaining 15/43 cases (34.9%), clinical follow-up and serial imaging were performed over a median

### Table 1 (continued)

| Distribution of the lesion | All cases n = 311 (%) | Diagnostic biopsy n (%) | Non-diagnostic biopsy n (%) | p value |
|----------------------------|-----------------------|-------------------------|-----------------------------|---------|
| Supratentorial              | 293 (94.2)            | 252 (86.0)              | 41 (14.0)                   | 0.892   |
| Infratentorial              | 1 (0.3)               | 1 (100)                 | 0 (0.0)                     |         |
| Supratentorial and infratentorial | 17 (5.5)         | 15 (88.2)               | 2 (11.8)                    |         |
| Region                     |                       |                         |                             |         |
| Frontal                    | 52 (16.7)             | 44 (84.6)               | 8 (15.4)                    | 0.245   |
| Parietal                   | 57 (18.3)             | 50 (87.7)               | 7 (12.3)                    |         |
| Temporal                   | 48 (15.4)             | 38 (79.2)               | 10 (20.8)                   |         |
| Occipital                  | 25 (8.0)              | 24 (96.0)               | 1 (4.9)                     |         |
| Brainstem, diencephalon, mesencephalon, midline structures | 24 (7.7) | 22 (91.7) | 2 (8.3) | |
| Basal ganglia              | 14 (4.5)              | 13 (92.9)               | 1 (7.1)                     |         |
| Thalamus                   | 15 (4.8)              | 15 (100)                | 0 (0.0)                     |         |
| Multiple regions           | 76 (24.4)             | 62 (81.6)               | 14 (18.4)                   |         |
| Size                       |                       |                         |                             |         |
| < 1 cm³                    | 22 (7.1)              | 9 (40.9)                | 13 (59.1)                   | < 0.001 |
| > 1 cm³                    | 289 (92.9)            | 259 (89.6)              | 30 (10.4)                   |         |
| Unilocular/multilocular    |                       |                         |                             |         |
| Unifocal                   | 211 (67.8)            | 187 (88.6)              | 24 (11.4)                   | 0.069   |
| Multifocal                 | 100 (32.2)            | 81 (81.0)               | 19 (19.0)                   |         |
| Contrast enhancement       |                       |                         |                             |         |
| Present                    | 247 (79.4)            | 223 (90.3)              | 24 (9.7)                    | < 0.001 |
| Perilesional edema         |                       |                         |                             | < 0.001 |
| Laboratory results before biopsy |                   |                         |                             |         |
| Abnormal CSF findings (lab)| 75 (65.8)             | 53 (69.3)               | 23 (30.7)                   | 0.143   |
| Abnormal CSF (neuropathology)| 23 (40.4)           | 21 (91.3)               | 2 (8.7)                     | 0.149   |
| Abnormal CSF (microbiology)| 2 (5.1%)              | 2 (100)                 | 0 (0)                       | 0.394   |
| Abnormal CSF (virology)    | 10 (12.8)             | 6 (60.0)                | 4 (40.0)                    | 0.265   |
| Stereotactic system        |                       |                         |                             |         |
| KD Lerch                   | 90 (28.9)             | 71 (78.9)               | 19 (21.1)                   | 0.023   |
| Leksell                    | 112 (36.0)            | 103 (92.0)              | 9 (8.0)                     |         |
| VarioGuide                 | 76 (24.4)             | 63 (82.9)               | 13 (17.1)                   |         |
| ZD                         | 33 (10.6)             | 31 (93.9%)              | 2 (6.1)                     |         |

IQR, interquartile range; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; ZD, Zamorano-Duchovny
follow-up time of 24 months (range: 1–88). 8/15 cases were lost to follow-up. In no case, a progression of the underlying disease occurred during follow-up. No specific treatment was necessary to maintain the good neurological status of these patients.

**Discussion**

We performed an analysis of the diagnostic yield, outcome, and management in 311 patients after stereotactic biopsy for an intracranial lesion with special regard to predictors for non-diagnostic biopsies.

### Diagnostic yield according to suspected diagnoses

The overall diagnostic yield in our study was 86.2%, which, at first glance, appears to be low in comparison with other recently published series, ranging between 88.1 and 98.2% [1, 4, 12, 17, 23]. However, we included a significant number of patients with non-neoplastic lesions. Our data revealed that the frequency of

| Neuropathological diagnosis                  | n (%) |
|---------------------------------------------|-------|
| Primary glial brain tumor                   | 145 (46.6) |
| Glioblastoma WHO IV                         | 69    |
| Anaplastic astrocytoma WHO III              | 36    |
| Diffuse astrocytoma WHO II                  | 36    |
| Diffuse midline glioma WHO IV               | 4     |
| Molecular diagnosis in glioma patients      |       |
| IDH status obtained                         | 121 (83.4) |
| Wildtype                                    | 100   |
| Mutated                                     | 21    |
| MGMT status obtained*                       | 90 (82.6) |
| MGMT unmethylated*                          | 41    |
| MGMT methylated*                            | 49    |
| 1p/19q codeletion status obtained           | 11 (7.6) |
| 1p/19q codeletion                           | 0     |
| Lymphoma                                    |       |
| Primary CNS lymphoma (DLBCL)                | 45    |
| Secondary CNS lymphoma                      | 6     |
| Other tumors                                |       |
| Metastasis                                  | 4     |
| Histiocytosis                               | 2     |
| Germial tumor                               | 2     |
| Meningioma                                  | 1     |
| Vascular                                    |       |
| Vasculitis                                  | 6     |
| Old hemorrhage/infarction                   | 10    |
| Amyloid angiopathy                          | 2     |
| Inflammatory (infectious)                   |       |
| Abscess                                     | 19    |
| PML                                         | 4     |
| Opportunistic infection                     | 1     |
| Encephalitis                                | 6     |
| Inflammatory (autoimmune)                  |       |
| CNS degenerative diseases                   | 8     |
| Encephalitis                                | 7     |
| Non-diagnostic                              |       |
| Unspecific reactive changes                 | 43 (13.8) |

*PML*, progressive multifocal leukoencephalopathy; *CNS*, central nervous system; *MGMT*, O6-methylguanine-DNA methyltransferase; *DLBCL*, diffuse large B cell lymphoma; *IDH*, isocitrate dehydrogenase

“*” refers only to high-grade gliomas (n = 109)
non-diagnostic biopsies was higher among patients with non-neoplastic lesions (89.7% for neoplastic lesions vs. 73.3% for non-neoplastic lesions, \( p = 0.001 \)). These findings are in accordance with the current literature [5, 15, 21, 28]. Often brain biopsies are requested by neurologists as an ancillary procedure, e.g., in cases of unclear neurological decline and inability of non-invasive investigations to yield in a diagnosis or failure of empirical treatment strategies. In our series, 17 patients underwent stereotactic brain biopsy, suspecting vasculitis. We found a diagnostic yield of 47.1% in comparison with other studies that report frequencies of 36% [3].

Although the diagnostic yield for non-neoplastic lesions is comparably low, it still reaches 73.3% in our series. Considering the low morbidity and mortality observed in our study and demonstrated by various other publications [6, 7, 16, 27, 29], the propensity of this procedure for establishing a diagnosis in a high percentage of such cases with unclear neurological deterioration justifies performing a brain biopsy, after exploiting all non-surgical diagnostic tests. This concept is supported by other groups [24, 30].

**Predictive factors for diagnostic yield and non-diagnostic biopsies**

In order to further improve the diagnostic yield, we aimed at analyzing predictors for non-diagnostic

| Table 3 Multivariate logistic regression model predicting a diagnostic sample |

| Diagnostic biopsy | OR  | 95% CI | \( p \) value |
|-------------------|-----|--------|---------------|
| Included variables: age, hemato-oncological disease, sepsis, immunosuppression, contrast-enhancing lesion, perilesional edema, size of the lesion, suspected diagnosis, stereotactic system (KD Lerch, Leksell, VarioGuide, ZD) |
| Hemato-oncological disease | Yes | Ref  |     |
| | No  | 4.42 | 1.01 | 19.35 | 0.049 |
| Sepsis | Yes | Ref  |     |
| | No  | 19.68 | 2.55 | 152.11 | 0.004 |
| Contrast-enhancing lesion | Yes | Ref  |     |
| | No  | 4.93 | 1.54 | 15.76 | 0.007 |
| Perilesional edema | Yes | Ref  |     |
| | No  | 3.23 | 1.07 | 9.71  | 0.037 |
| Size of lesion | \( \leq 1 \text{ cm}^3 \) | Ref  |     |
| | \( > 1 \text{ cm}^3 \) | 7.51 | 2.07 | 27.18 | 0.002 |
| Stereotactic system | KD Lerch | Ref  |     |
| | Leksell | 5.89 | 1.94 | 17.79 | 0.002 |
| | VarioGuide | 2.34 | 0.82 | 6.68  | n.s. |
| | ZD | 8.97 | 1.45 | 55.63 | 0.018 |

\( OR \), odds ration; \( 95\% CI \), 95% confidence interval; \( Ref \), reference; \( ZD \), Zamorano-Duchovny
biopsies and found several factors that influence the likelihood of a non-diagnostic probe.

The presence of an underlying hemato-oncological disorder, e.g., leukemia (OR: 4.4) and sepsis (OR: 19.7) was strongly associated with non-diagnostic biopsies. This patient group is more likely to have non-neoplastic cerebral lesions associated with unspecific inflammatory reactions, which is challenging to be detected via small core biopsies [21]. This stands in contrary to the findings of a study on pediatric patients with cryptogenic brain lesions and a study analyzing patients with neurological diseases of unknown etiology, revealing that immunocompromised patients were more likely to yield a diagnosis at biopsy [18, 22, 26]. Radiological features such as the presence of contrast enhancement (OR: 4.9) and perilesional edema (OR: 3.2), as can be observed in most malignant neoplastic lesions or abscesses, were found to be associated with a higher likelihood of a diagnostic biopsy. Lara-Almunia et al. confirmed the presence of contrast-enhancement as a predictor for a diagnostic biopsy. However, they report the presence of significant edema as being associated with a non-diagnostic probe [17] which we could not confirm in our cohort.

In addition, our analysis showed that it is more likely to obtain a diagnostic biopsy from a lesion with a size of more than 1 cm³ than from smaller lesions (OR: 7.5). These data are confirmed by other studies [21, 28, 29, 31, 32]. Maragkos et al. showed in their cohort of 198 patients that for every additional mm of lesion diameter, the odds of yielding a diagnostic sample increases by 94% [21]. Smaller lesions are more likely to be missed by the surgeon and handling and analysis of limited tissue probes are challenging for the neuropathologists [21, 29]. It has been shown that overall diagnostic accuracy achieved on histopathology correlates with the amount of tissue obtained during biopsy [14].

We found mainly non-modifiable variables to be associated with a non-diagnostic probe. However, other modifiable

---

**Table 4 Complications and mortality rate after stereotactic biopsy**

| Type of complication | n (%)   |
|---------------------|---------|
| Complication        | 21 (6.8)  |
| Symptomatic hemorrhage | 9 (2.9)  |
| Surgical site infection | 1 (0.3)  |
| New neurological deficit | 17 (5.5) |
| Decompensation of underlying pathology, massive cerebral edema | 5 (1.6)  |
| Reoperation due to complication | 9 (2.9)  |
| 30-day mortality    | 14 (4.5) |
| Procedure-related mortality | 2 (0.6)  |

---

**Fig. 2** Overview on management after non-diagnostic biopsy
predictors, such as performance of intraoperative frozen section examinations [15], MRI- [9], and FDG-PET-guided biopsies [17, 19] are reported in the literature. Some studies reported the neurosurgeon’s experience as a pre-eminent predictive factor for diagnostic yield [17, 25] and revealed an impact of the anatomic location [7, 31].

The only modifiable factor in our study was the choice of the frame. We reached the lowest rate of non-diagnostic biopsies using ZD stereotactic system, which might also be biased by other factors as the choice and experience of the individual surgeon. However, we observed no significant difference regarding the use of frameless or frame-based systems, which is in accordance with the literature [7, 14, 31, 32] and a recently published meta-analysis [8].

We routinely take biopsies from multiple points along the biopsy trajectory, always balancing a potential increase in diagnostic yield against a possible increased risk of neurological deficit. However, our data did not allow analyzing the impact of the number of biopsies on the diagnostic yield. We believe that obtaining tissue from more than one target might improve diagnosis especially in heterogenous lesions.

Complications and 30-day mortality

We noted a procedure-related mortality rate of 0.6% and morbidity rate of 6.8%. These results are comparable with those reported in the literature, where the morbidity rate ranges between 0.5 and 13% and the mortality rate between 0 and 4%, respectively [6, 7, 16, 26, 27, 29].

Still, there is a non-deniable rate of morbidity after stereotactic biopsy that has to be balanced against the potential gain regarding a diagnosis especially in non-neoplastic cases or cases that have a higher risk for non-diagnostic biopsy. Biopsies in such cases should only be performed after extensive conventional and non-invasive diagnostic procedures have proved to be inconclusive.

Fig. 3 Patient was admitted to neurosurgery with FLAIR hyperintense lesion (a, left panel) with partial ring enhancement and perifocal edema (a, right panel) highly suggestive for high-grade brain tumor. Biopsy planning included CT-based navigation (b). CT after first biopsy reveals small air bubble representing sample location mostly within perifocal edema (c). Since first biopsy result was non-conclusive, re-biopsy was planned using contrast-enhanced CT with stereotactic frame (d). CT after second biopsy shows a more central sampling as suggested by an according air bubble (e). Second biopsy revealed glioblastoma as diagnosis.
Management of patients with non-diagnostic biopsies

Despite paying attention to factors that are associated with non-diagnostic biopsies during surgical planning, there are still cases that are left without revealing a diagnosis. There is still a lack of treatment and management paradigm for such cases [2, 32]. In total, 43 patients (13.8%) that differed regarding their suspected underlying disease and clinical presentations revealed a non-diagnostic biopsy result. Regarding further management, these patients can be divided into three groups. In 12 cases (27.9%), a re-biopsy was performed due to highly suspected tumor (Fig. 3). In 8 of these 12 cases (66.7%), a diagnosis could be obtained and initial biopsy underlay a target error. In 4 cases (33.3%), the repeat biopsy remained non-diagnostic. However, a close follow-up of these patients did not show any signs of clinical or morphological progression of the underlying lesion.

Patients from the second group (n = 16, 37.2%) were empirically treated antiviral, antibacterial, or antimycotic agents or immunosuppression according to the suspected diagnosis provided by clinical and imaging findings. All patients with sufficient follow-up improved clinically (Fig. 4). A further group of 15 patients (34.8%), mainly patients without neurological deficits in a good clinical condition, underwent clinical follow-up and repeat cranial imaging (Fig. 5). We observed that the non-diagnostic biopsies did not affect the patient’s outcome adversely. These findings are similar to the study by Air et al. and Zoellner et al. [2, 32].

In cases of non-diagnostic biopsies, we recommend early postoperative imaging to confirm the intended biopsy location. Repeat biopsy should be performed when the target was missed. If the lesion was accessed and pathology is inconclusive, management depends on the suspected underlying diagnosis. In case of strong evidence for a tumor, re-biopsy or open resection depending on size and location of the mass should be considered. However, when primarily suspecting a neurological disorder, e.g., vasculitis or neurodegenerative disease, we recommend empiric treatment and re-evaluation,

![Image](https://example.com/image.jpg)

Fig. 4 Patient was admitted with suspected cerebral vasculitis. MRI showed small restriction in diffusion within the left corona radiata (a, DWI left and ADC map right panel) as well as elder cortical and subcortical postischaemic lesions within the right hemisphere (b). TOF angiography revealed small arteria basilaris and bilateral occluded proximal arteria cerebri posterior (c), which were peripherally collateralized from anterior circulation. Since further diagnostic procedures were not fully conclusive, patient was planned for biopsy. Empiric treatment for vasculitis was initiated after non-diagnostic biopsy. Patient showed a clinical treatment response under empiric therapy and no new lesions in MRI at follow-up (d)
as the diagnostic yield for those lesions appears to be lower and the main contribution of the biopsy in those cases is the exclusion of a neoplasm [25]. In cases of clinical or morphological progression under therapy and/or lack of response to treatment, we recommend a repeat biopsy. Obviously, these rare cases are subject to interdisciplinary discussion on an individual case base taking the patients’ clinical and neurological status, other diagnostic findings, and the retrieved pathological results into account.

Limitations

Due to the retrospective character of the study, it faces some limitations. Patient care was continued in several cases at the referring hospital, explaining a lack of long-term follow-up data of those cases. Patient selection and determination of various treatment options is an important factor when analyzing these results as the study overlooks a long period with several surgeons responsible for treatment algorithms.

However, all cases were discussed in a multidisciplinary manner prior to surgery. There are likely more factors associated with non-diagnostic biopsies, e.g., the needle trajectory or angle of approach, that were not subject to analysis in this study. We recommend the inclusion of those factors in future prospective studies.

Conclusions

We show that stereotactic biopsy is a safe procedure and provides a reasonable diagnostic yield even in cases with non-neoplastic lesions, when non-invasive diagnostic was inconclusive. Our study revealed that the likelihood of a non-diagnostic biopsy was significantly higher in patients with non-neoplastic lesions. Management of patients with inconclusive biopsies should be based on the initial assumption of the etiology of the lesion prior to surgery. In case of strongly suspected tumor, biopsy should be repeated and in case of
suspected non-neoplastic lesion, such as inflammatory or neurodegenerative empirical treatment and/or close follow-up are recommended.

**Acknowledgments** Dr. Schipmann acknowledges the Medical Faculty of the Westphalian Wilhelm University of Münster for their support.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Compliance with ethical standards**

**Conflict of interest** Professor Stummer reports consultant and lecture activities for medac (Wedel, Germany), Carl Zeiss Meditec (Oberkochen, Germany), and NxDc (Lexington, Kentucky).

All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Ethics commission, Westphalian Wilhelms University Münster, Ref 2019-379-FS) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Consent to participate** Informed consent was obtained from all individual participants or their legally authorized representatives included in the study.

**Consent to publish** No data is published that enables identifying individual participants.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Aebelo A, Noer VR, Schulz MK, Kristensen BW, Pedersen CB, Poulsen FR (2019) Frameless stereotactic neuronavigated biopsy: a retrospective study of morbidity, diagnostic yield, and the potential of fluorescence: a single-center clinical investigation. Clin Neurol Neurosurg 181:28–32. https://doi.org/10.1016/j.clineuro.2019.03.004

2. Air EL, Warnick RE, McPherson CM (2012) Management strategies after nondiagnostic results with frameless stereotactic needle biopsy: retrospective review of 28 patients. Surg Neurol Int 3: S315–S319. https://doi.org/10.4103/2152-7806.103026

3. Alrawi A, Trobe JD, Blaivas M, Musch DC (1999) Brain biopsy in primary angiitis of the central nervous system. Neurology 53:858–860. https://doi.org/10.1212/wnl.53.4.858

4. Blauw G, Braakman R (1988) Pitfalls in diagnostic stereotactic brain surgery. Acta Neurochir Suppl (Wien) 42:161–165. https://doi.org/10.1007/978-3-7091-8975-7_32

5. Brainard JA, Prayson RA, Barnett GH (1997) Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121:481–484

6. Chen CC, Hsu PW, Erich Wu TW, Lee ST, Chang CN, Wei KC, Chuang CC, Wu CT, Lui TN, Hsu YH, Lin TK, Lee SC, Huang YC (2009) Stereotactic brain biopsy: single center retrospective analysis of complications. Clin Neurol Neurosurg 111:835–839. https://doi.org/10.1016/j.clineuro.2009.08.013

7. Dammers R, Haismsa IK, Schouten JW, Kros CV, Valery C, Oppenheim C, Sahel M, Marsault C, Philippe J, Cornu P (2000) Magnetic resonance-guided stereotactic biopsies: results in 100 consecutive cases. Acta Neurochir 142:249–255; discussion 255-246. https://doi.org/10.1007/s007010050032

8. Dhawan S, He Y, Bartek J Jr, Alattar AA, Chen CC (2019) Comparison of frame-based versus frameless intracranial stereotactic biopsy: systematic review and meta-analysis. World Neurosurg 127:607–616 e604. https://doi.org/10.1016/j.wneu.2019.04.016

9. Fontaine D, Dormont D, Hasboun D, Clemenceau S, Valery C, Oppenheim C, Sahel M, Marsault C, Philippe J, Cornu P (2000) Magnetic resonance-guided stereotactic biopsies: results in 100 consecutive cases. Acta Neurochir 142:249–255; discussion 255-246. https://doi.org/10.1007/s007010050032

10. Gemp J, Buchmann N, Ryang YM, Krieg S, Kreutzer J, Meyer B, Ringel F (2012) Frameless image-guided stereotaxy with real-time visual feedback for brain biopsy. Acta Neurochir 154:1663–1667. https://doi.org/10.1007/s00701-012-1425-y

11. Gildenberg PL (2013) The birth of human stereotactic surgery. Acta Neurochir Suppl 117:1–4. https://doi.org/10.1007/978-3-7091-1482-7_1

12. Hakan T, Aker FV (2016) Evaluation of 126 consecutive stereotactic procedures: brain biopsy, diagnostic yield, accuracy, nondiagnostic results, complications and follow-up. Turk Neurosurg 26:890–899. https://doi.org/10.5137/1019-5149.TJNS13742-14.0

13. Hamisch CA, Minartz J, Blau T, Hafkemeyer V, Ruess D, Hellerbach A, Grau SJ, Ruge MI (2019) Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield. Acta Neurochir 161: 2065–2071. https://doi.org/10.1007/s00701-019-04020-1

14. Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK (2006) Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 23:71–75. https://doi.org/10.1007/s10014-006-0204-y

15. Kim JE, Kim DG, Paek SH, Jung HW (2003) Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. Acta Neurochir 145:547–554; discussion 554-545. https://doi.org/10.1007/s00701-003-0488-8

16. Kongkham PN, Kniedf E, Tamber MS, Bernstein M (2008) Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. Can J Neurol Sci 35:79–84. https://doi.org/10.1017/s0317167100007605

17. Lara-Almunia M, Hernandez-Vicente J (2019) Frame-based stereotactic biopsy: description and association of anatomical, radiologic, and surgical variables with diagnostic yield in a series of 407 cases. J Neurol Surg A Cent Eur Neurosurg 80:149–161. https://doi.org/10.1055/s-0038-1676597

18. Layard Horsfall H, Toescu SM, Grover PJ, Hassell J, Sayer C, Hemingway C, Harding B, Jacques TS, Aquilina K (2020) The utility of brain biopsy in pediatric cryptogenic neurological disease.
19. Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, Hildebrand J, Brochet J (1995) Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 82:445–452. https://doi.org/10.3171/jns.1995.82.3.0445

20. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

21. Maragkos GA, Penumaka A, Ahrendsen JT, Salem MM, Nelton EB, Alterman RL (2020) Factors affecting the diagnostic yield of frame-based stereotactic intracranial biopsies. World Neurosurg 135:e695–e701. https://doi.org/10.1016/j.wneu.2019.12.102

22. Mathon B, Le Joncour A, Bielle F, Mokhtari K, Boch AL, Peyre M, Amoura Z, Cacoub P, Younan N, Demeret S, Shotar E, Burrel S, Fekkar A, Robert J, Amelot A, Pineton de Chambrun M, Psl Brain-Biopsy Study G (2020) Neurological diseases of unknown etiology: brain-biopsy diagnostic yields and safety. Eur J Intern Med. https://doi.org/10.1016/j.ejim.2020.05.029

23. Paleologos TS, Dorward NL, Wadley JP, Thomas DG (2001) Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases. Neurosurgery 49:830–835; discussion 835-837. https://doi.org/10.1097/00006123-200110000-00009

24. Pulhorn H, Quigley DG, Bosma JJ, Kirollos R, du Plessis DG, Jenkinson MD (2008) Impact of brain biopsy on the management of patients with nonneoplastic undiagnosed neurological disorders. Neurosurgery 62:833–837; discussion 837-838. https://doi.org/10.1227/01.neu.0000318168.97966.17

25. Ranjan A, Rajeshkhar V, Joseph T, Chandy MJ, Chandi SM (1993) Nondiagnostic CT-guided stereotactic biopsies in a series of 407 cases: influence of CT morphology and operator experience. J Neurosurg 79:839–844. https://doi.org/10.3171/jns.1993.79.6.0839

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.